Hormone Replacement Therapy Market Size Expected to Reach USD 21.49 Billion, exhibiting a CAGR of 6.1% by 2028
April 13, 2023 02:38 ET
|
Fortune Business Insights
Pune, India, April 13, 2023 (GLOBE NEWSWIRE) -- The global hormone replacement therapy market size was USD 13.40 billion in 2020. The market is projected to grow from USD 14.17 billion in 2021 to...
Global Biopharmaceutical Market to Generate USD 974.48 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
August 02, 2022 06:41 ET
|
Next Move Strategy Consulting
New York, Aug. 02, 2022 (GLOBE NEWSWIRE) -- According to the report published by Next Move Strategy Consulting, the global biopharmaceutical market generated USD 345.84 billion in 2021, and is...
Metabolomics Services Market Size ($1,895.14Mn by 2028) Led by Targeted Metabolomics Service (20.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 27, 2021 14:11 ET
|
The Insight Partners
New York, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Metabolomics Services Market: Key InsightsAccording to our new research study on “Metabolomics Services Market Size and Forecast to 2028 - COVID-19 Impact...
Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
September 07, 2017 07:50 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE...
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
August 03, 2017 08:23 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced the pricing of its underwritten public...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics Reports First Quarter 2017 Financial Results
May 08, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three months ended March 31, 2017, and...
Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
April 27, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...
ITL Pharma Receives United States Patent Protection for TriThroid® Using Sustained Drug Release and Improved Product Stability
February 14, 2017 09:10 ET
|
ITL Pharma, Inc.
KINGSPORT, Tenn., Feb. 14, 2017 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Research Company, today announced awarding of a United States Patent (US 9,526,701) titled: "Sustained Drug Release...